ABSTRACT
INTRODUCTION
Chlamydia trachomatis is responsible for trachoma and sexually transmissible diseases in human. This bacterium is obligate intracellular parasite and use host cell energy system. Genital tract infection with chlamydia is common in some countries (1).
Serotypes L3, L2, L1, D, and K of C. trachomatis cause genital tract infections. Some infections of genital tract of women are often asymptomatic. With the progresses of the disease, symptoms may appear (2). C. trachomatis is causative of cervicitis, endometritis, salpengitis, prehepatitis bartonellosis in women (3). Complications of untreated chlamydial infections may occur and these include pelvic inflammatory disease, ectopic pregnancy, fallopian tube obstruction, infertility, cervical dysplasia, and prehepatitis (4). Prevalence of chlamydial infections of genital tracts among pregnant women in Western countries is about 5-13 percent (5) . 33-50% of infants of infected mothers get chlamydial infections such as conjunctivitis, nasopharyngitis, otitis media and neonatal Chlamydia pneumonia during passage through the birth canal (6-9). Studies showed 35-50% of non-gonococcal urethritis (NGU) and a maximum of 70% of subsequent gonorrhea urethritis (post gonococcal urethritis = PGU) are caused by chlamydia (10) .
Because of the importance of early and accurate diagnosis of chlamydial infection and its role in the health system, this study was aimed to use recombinant chlamydia OMP2 protein as an antigen in diagnostic ELISA Kit.
MATERIALS AND METHODS
Sampling. Blood samples from 192 women with suspected C. trachomatis infection refereed by physician and 40 healthy women (controls) were collected. Sera samples were separated and divided into small tubes and maintained at -20°C.
Preparation of antigen. BL21 E. coli bacterial colony containing C. trachomatis OMP2 gene construct (11) was cultured. When the turbidity of the culture reached to OD600 = 0.6 plasmid promoter was induced by 0.5mM IPTG (USA, Sigma) and bacteria were precipitated after 5 h and lysed by sonication. OMP2 C. trachomatis recombinant protein was purified by Ni-NTA affinity chromatography (12). The wells of ELISA plates were coated with recombinant protein as previously described (11).
Cut off determination. Forty negative C. trachomatis sera were examined by ELISA to determine system Cut-off. The graph and The samples evaluation by ELISA. 192 chlamydial infections suspected sera samples were tested by recombinant omp2 coated plate and Euroimmun commercial kit. The amount of antigen was 3 mg and sera were diluted at 1/400, but better results were taken at 1/200. The sensitivity and specificity of ELISA with recombinant protein and commercial kit were calculated using formula: Cut off = mean + 2SD.
The Cut off for 1/400 serum dilution was 0.244 (0.116 + 2 X 0.064) and for 1/200 serum dilution was 0.271(0.127 + 2 X 0.072). We used 0.271 as cut-off for ELISA test carry out.
Specificity and Sensitivity were determined using the formula: Specificity = number of true negative/number of true negative + number of false positive X100 Sensitivity = number of true positive/number of true positive + number of false negative X 100
The T-student statistical method was used to analyse of the results.
RESULTS
Sera were collected from 192 suspected patients infected with Chlamydia trachomatis. C. trachomatis rOMP2 was purified by affinity chromatography and ELISA plate wells were coated with it. Forty seronegative samples were tested and 0.271 were considered as cut-off for this ELISA system.
For specificity of system, the sera with other infections were examined by this protein. There were no cross-reactivity between rOMP2 protein and sera with other infections (Fig. 1) . Fig. 2 shows comparison of Cut Off for 40 negative sera at 1/200 and 1/400 dilutions and 3 mg/ml rOMP2.
We tested antigen concentration for coating on microplate wells with 3 mg/ml and 2 mg/ml and used for serum concentration (Fig. 3) . The OD of 192 C. trachomatis suspected serum were calculated by rOMP2 and Euroimmun commercial kit as shown in Figs. 4 and 5.
According to Table 1 The specificity and sensitivity of ELISA were calculated 86 and 90% for rOMP2 protein and 97.1 and 78.2 for Euroimmun commercial kit, respectively. Therefore rOMP2 protein for ELISA is more sensitive and less specific than Euroimmun commercial kit. For specificity of system, the sera with other infections were examined by this protein. There were no cross-reactivity between rOMP2 protein and sera with other infections (Fig.1) . We tested antigen concentration for coating on microplate wells with 3 mg/ml and 2 mg/ml and used for serum concentration (Fig.3) . The OD of 192 C. trachomatis suspected serum were calculated by rOMP2 and Euroimmun commercial kit as shown in Figs. 4 and 5. We tested antigen concentration for coating on microplate wells with 3 mg/ml and 2 mg/ml and used for serum concentration (Fig.3) . The OD of 192 C. trachomatis suspected serum were calculated by rOMP2 and Euroimmun commercial kit as shown in Figs. 4 and 5.
Fig. 1. Evaluation of cross-reactivity between

Fig. 3.
Comparison of sera dilutions with 3mg/mL and 2mg/mL of rOMP2 protein There were 7 positive samples (3.83%) and 173 negative samples (96.1%) of 180 suspected C. trachomatis sera by Euroimmun commercial ELISA kit. The specificity and sensitivity of Euroimmun ELISA kit were 97.1% and 78.2% respectively, whereas those of rOMP2 were 86% and 90%. That means ELISA assay with recombinant protein rOMP2 antigen is more sensitive but the commercial kit is more specific. Bas et al. reported 76% sensitivity and 85% specificity for recombinant protein and synthetic peptides in ELISA system (15).
OMP2 is an extra membrane protein of C. trachomatis and was described as cysteine-rich protein (containing 24 disulfide bonds) with 60 kDa by Allen in 1989 for the first time (17). Portig et al. declared that OMP2 is a properly antigen in ELISA system for detection of chlamydial infections (18).
In conclusion, the sensitivity and specificity of rOMP2 in ELISA for detection of C. trachomatis are 90% and 86%, respectively, which is more sensitive than Euroimmun commercial and its specificity is lower than Euroimmun commercial kit
